Figures
Abstract
Apoptosis signal-regulating kinase 1 (ASK1), a member of the mitogen-activated protein kinase 3 family, is activated by oxidative stress. The death-signaling pathway mediated by ASK1 is inhibited by DJ-1, which is linked to recessively inherited Parkinson's disease (PD). Considering that DJ-1 deficiency exacerbates the toxicity of the mitochondrial complex I inhibitor 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), we sought to investigate the direct role and mechanism of ASK1 in MPTP-induced dopamine neuron toxicity. In the present study, we found that MPTP administration to wild-type mice activates ASK1 in the midbrain. In ASK1 null mice, MPTP-induced motor impairment was less profound, and striatal dopamine content and nigral dopamine neuron counts were relatively preserved compared to wild-type littermates. Further, microglia and astrocyte activation seen in wild-type mice challenged with MPTP was markedly attenuated in ASK1−/− mice. These data suggest that ASK1 is a key player in MPTP-induced glial activation linking oxidative stress with neuroinflammation, two well recognized pathogenetic factors in PD. These findings demonstrate that ASK1 is an important effector of MPTP-induced toxicity and suggest that inhibiting this kinase is a plausible therapeutic strategy for protecting dopamine neurons in PD.
Citation: Lee K-W, Zhao X, Im J-Y, Grosso H, Jang WH, Chan TW, et al. (2012) Apoptosis Signal-Regulating Kinase 1 Mediates MPTP Toxicity and Regulates Glial Activation. PLoS ONE 7(1): e29935. https://doi.org/10.1371/journal.pone.0029935
Editor: Mark R. Cookson, National Institutes of Health, United States of America
Received: July 29, 2011; Accepted: December 7, 2011; Published: January 10, 2012
Copyright: © 2012 Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by NINDS/NIH grants NS059869 and NS53517 to M.M.M. and by grants from the American Parkinson Disease Association and the Foundation of UMDNJ to E.J. M.M.M. is the William Dow Lovett Professor of Neurology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Parkinson's disease (PD) is a common neurodegenerative disorder in which dopaminergic neurons of the substantia nigra bear the brunt of the pathology. A consistent biochemical abnormality in this brain region documented in postmortem studies is oxidative stress with distinct markers of damage to cellular proteins, lipids and DNA [1]. These findings, along with the realization that agents that are toxic to dopaminergic neurons in vitro and in vivo cause increased intracellular levels of reactive oxygen species, have led to the use of those toxins to generate animal models of PD. Among these toxins, MPTP is a mitochondrial complex I inhibitor that causes parkinsonian features in humans and primates, and recapitulates dopaminergic deficits in the nigrostriatal pathway of mice [2], [3]. Therefore, MPTP is widely used as a tool to study the molecular events that lead to degeneration of dopaminergic neurons in animal models of PD and to test potentially neuroprotective agents.
Several genes have been linked to familial forms of PD. Among these, DJ-1, which causes recessively inherited disease when mutated, encodes a neuroprotective protein that has antioxidant activity [4]. In addition, we reported previously that DJ-1 achieves its cytoprotective function by interfering with the activation of Apoptosis Signal-Regulating Kinase 1 (ASK1) signaling pathway [5], suggesting that the latter might be involved in the pathogenesis of PD.
ASK1 is a member of the MAP3 kinase family that activates JNK and p38 kinase pathways [6], [7]. In addition to Fas-induced, Daxx-mediated activation [8], ASK1 is activated by various stimuli including oxidative stress [9], [10], endoplasmic reticulum stress [11] and TNF-α [12], and relays those signals to JNK and p38 [8] leading to apoptosis [9]. A number of studies have suggested that ASK1 is functional in neural tissues. Its mRNA is expressed in brain, including in cortex, hippocampus, olfactory bulb and striatum [13], and expression of a constitutively active form of ASK1 induces neurite outgrowth in the rat pheochromocytoma PC12 cell line [14]. In addition, the requirement of ASK1 activation has been demonstrated in an ALS mouse model expressing mutant form of SOD1 [15]. In a recent postmortem study of PD affected brains, ASK1 was found to be activated in substantia nigra neurons compared to control brains [16]. Further, ASK1−/− primary neurons are resistant to cell death induced by ER stress, proteasome dysfunction, and expanded polyglutamine expression [11], and ASK1 knockdown using shRNA in the mouse nigra diminishes 6-hydroxydopamine toxicity [16]. Thus, ASK1 is a key player in mediating the effects of various cellular insults.
Here, we show that MPTP administration activates ASK1 in the substantia nigra of wild-type mice, while deleting the ASK1 gene confers relative resistance to this toxin demonstrated by biochemical, histopathological and behavioral analyses. Our results indicate that blocking ASK1 expression can mitigate the dopaminergic neuron loss that follows MPTP intoxication and suppresses glial activation in the nigra and striatum. These findings suggest that ASK1 signaling plays an important role in MPTP-induced toxicity in mice by linking the oxidative stress generated by MPTP and the associated neuroinflammation. Controlling ASK1 activity may ultimately help design new neuroprotective therapeutic interventions for PD and other neurodegenerative disorders in which oxidative stress plays a significant pathogenetic role.
Results
ASK1 is activated by oxidative stress in cultured cells and in vivo
Since ASK1 is known to be a key player in oxidative stress-induced cell signaling, we examined whether MPTP-induced dopaminergic cell death is associated with ASK1 activation. First, dopaminergic neuroblastoma SH-SY5Y cells were challenged with MPP+, and processed for in vitro kinase assay of ASK1. A significant increase in ASK1 activity was seen as early as 10 minutes after MPP+ treatment (Fig. 1A). We also observed ASK1 activation in primary rat cortical neurons following H2O2 challenge (1 mM) detected by a transient increase in the amount of phosphorylated ASK1 (Fig. 1B) as reported previously [17]. Next, we investigated the levels of phosphorylated ASK1 following MPTP administration into mice. Wild-type C57BL/6J mice were injected with MPTP (20 mg/kg every 2 h×4) or saline intraperitoneally and sacrificed 90 min after the last injection. Ventral midbrains containing substantia nigra pars compacta were processed for Western blotting using anti-phophorylated ASK1 antibody. MPTP administration significantly increased phosphorylated ASK1 level compared to saline-treated animals (Fig. 1C) consistent with previous reports [18], [19]. These findings indicate that ASK1 is activated in vitro and in vivo after insults that produce oxidative stress.
(A) ASK1 activation by MPP+. SH-SY5Y cells were challenged with 5 mM MPP+ and ASK1 activity measured by in vitro kinase (IVK) assay. Total ASK1 expression was checked by Western blotting. The bar graph on the right shows quantification of band intensities. (B) ASK1 phosphorylation with hydrogen peroxide treatment. Rat primary cortical neurons were challenged with 1 mM H2O2 followed by Western blotting for phospho-ASK1. The bar graph on the right shows quantification of the Western blot data. (C) ASK1 phosphorylation in MPTP-injected mice. Wild-type mice were injected with MPTP (20 mg/kg every 2 h×4) or saline intraperitoneally and sacrificed 90 minutes after the last injection. Midbrains containing substantia nigra from four saline treated mice and 5 MPTP challenged mice were homogenized and lysed for Western blotting with phospho-ASK1 antibody and total ASK1 antibody. The bar graph shows quantification of the Western blot data. * p<0.05.
ASK1 null mice are relatively resistant to MPTP
To address the role of ASK1 in the pathogenesis of PD, we compared the susceptibility of wild-type and ASK1−/− mice to MPTP. First, loss of ASK1 expression was confirmed by Western blotting of substantia nigra tissue lysates from ASK1−/− mice (Fig. 2A). MPTP was administered over 5 days (30 mg/kg/day) and animals were sacrificed 14 days after the last injection. The integrity of nigral dopaminergic neurons was assessed by stereological counting of TH positive neurons. Compared to about 35% loss of TH-positive neurons due to MPTP in wild-type mice, this figure was only about 13% in ASK1−/− animals (Fig. 2B). On the other hand, stereological counting of TH-negative, Nissl-stained neurons showed no change after MPTP in either group (Fig. 2C). The finding that TH-positive neurons decreased while TH-negative/Nissl stained neurons did not increase after MPTP compared to saline indicates degeneration of TH-positive neurons rather than merely decreased TH expression. Representative immunohistochemical images show marked degeneration of nigral dopaminergic neurons in MPTP challenged wild-type mice but a significantly attenuated effect in ASK1−/− mice (Fig. 2D).
(A) Western blot for ASK1 in substantia nigra tissue lysates from wild-type and ASK1−/− mice shows loss of the specific band in the latter group (arrow). The asterisk marks a nonspecific band. (B) Stereological counting of TH positive nigral dopamine neurons following MPTP or saline administration. * p<0.05. (C) Number of Nissl stained TH negative neurons. Saline-WT (n = 5), Saline-ASK1−/− (n = 5), MPTP-WT (n = 4), MPTP-ASK1−/− (n = 5). (D) Representative images of TH immunohistochemistry of midbrain sections from wild-type and ASK1−/− mice treated with saline or MPTP. Scale bar = 200 µm.
Striatal dopamine depletion is an important measure of dopaminergic neuron degeneration in PD and MPTP models. Two weeks after MPTP administration, striatal dopamine content decreased down to 28% in wild-type mice compared to saline injected animals. On the other hand, dopamine content in ASK1−/− mice decreased down to 45% (p<0.05) (Fig. 3A). Striatal tyrosine hydroxylase content measured by ELISA also showed a smaller decline after MPTP exposure in ASK1−/− mice compared to wild-type animals (32% residual TH in wild-type mice compared to 53% in ASK1−/− mice; p<0.01) (Fig. 3B). Immunohistochemical staining of the striatum for TH revealed a profile consistent with the ELISA data indicating that striatal dopaminergic terminals of ASK1−/− mice were relatively spared compared to their wild-type counterparts (Fig. 3C).
(A) Striatal dopamine content following MPTP or saline administration. * p<0.05. (B) TH content measured by ELISA in striatal tissue. ** p<0.01. Saline-WT (n = 5), Saline-ASK1−/− (n = 5), MPTP-WT (n = 4), MPTP-ASK1−/− (n = 5). (C) Representative images of immunohistochemical images for TH in striatum. Scale bar = 200 µm.
To exert its toxicity in vivo, MPTP is first converted to MPP+ by MAO-B activity. To confirm that the attenuated response of ASK1−/− mice to MPTP is not due to altered MPTP metabolism in this mouse line, we measured striatal MPP+ levels after MPTP intoxication. Ninety minutes after a single IP injection of 30 mg/kg MPTP, striatal MPP+ levels measured by HPLC were 3.65±0.42 ng/mg protein (n = 8) for ASK1−/− mice compared with 3.88±0.55 ng/mg protein for wild-type mice (n = 6). This lack of a difference indicates that MPTP metabolism is not altered as a result of ASK1 deletion, and, therefore, this possibility cannot account for the attenuated response of ASK1−/− mice to MPTP toxicity.
The motor manifestations of PD are due to the marked reduction in striatal dopamine content caused by the loss of dopaminergic nerve terminals in the striatum. Since ASK1 deficiency is associated with an attenuated response to MPTP toxicity, we investigated if ASK1−/− mice have a better locomotor and behavioral performance following MPTP intoxication compared to wild-type littermates. First, performance on the rotarod was evaluated 1 day after saline or MPTP (20 mg/kg every 2 h×4) treatment. Compared to the poor performance of wild-type mice after MPTP, ASK1−/− mice intoxicated with MPTP had longer latency to fall from the rotating bar indicating a better performance (Fig. 4A). Second, nest-building behavior, which requires orofacial and forelimb movements, is impaired after MPTP [20] and is dopamine-dependent [21], was evaluated 2 days after saline or MPTP (20 mg/kg every 2 h×4) administration. Compared with the 72% impairment in nest building ability in wild-type mice lesioned with MPTP vs saline, ASK1−/− animals had significant preservation of this behavior after MPTP (Fig. 4B,C). These results are consistent with the biochemical and stereological indices of dopaminergic system preservation in MPTP lesioned ASK1−/− mice.
(A) Performance on the Rotarod test one day post-MPTP. Saline-WT (n = 3), Saline-ASK1−/− (n = 6), MPTP-WT (n = 3), MPTP-ASK1−/− (n = 4). * p<0.05. (B, C) Nest building behavior two days post-MPTP scored after 18 hours in the cage with a square cotton Nestlet. Saline-WT (n = 3), Saline-ASK1−/− (n = 6), MPTP-WT (n = 3), MPTP-ASK1−/− (n = 4). * p<0.05.
Comparison of non-lesioned ASK1−/− mice with wild-type littermates following saline administration showed a modest elevation of striatal dopamine content (17.2±0.62 vs 15.2±0.43 ng/mg, respectively; p<0.03) as described previously [22]. This was associated with a parallel increase in nigral dopamine neuron count (4984±347 vs 3215±276, respectively; p<0.05). Behaviorally, these animals are also reported to be hyperactive in a novel environment and to have superior performance on the rotarod [22], although their trend of better performance in this study was not significant (Fig. 4A, B).
MPTP-induced glial activation is blunted in ASK1 null mice
Microglia activation is associated with the pathogenesis of PD and is an important player in MPTP toxicity [23], [24]. To determine if ASK1 is involved in MPTP-induced microglia activation, wild-type and ASK1−/− mice were subjected to the acute MPTP lesioning paradigm (20 mg/kg every 2 h×4), and brains were analyzed 1 day and 3 days after the last injection. Striatal and nigral sections were studied immunohistochemically using the microglial marker Iba1. Compared to the robust induction of Iba1 positive cells in the nigra of wild-type mice following MPTP, this response was significantly attenuated in ASK1−/− mice (Fig. 5A, C). In the striatum, the activation of microglia after MPTP intoxication observed in wild-type mice was also markedly blunted in ASK1−/− animals (Fig. 5B, D). Cyclooxygenase 2 (COX-2), the inducible form of the rate-limiting enzyme in prostaglandin synthesis, is increased in PD brains [25] and reportedly mediates microglia activation and subsequent dopamine neuron degeneration in the mouse MPTP model [26], [27]. Consistent with the significant attenuation in microglial activation following MPTP challenge in ASK1−/−, COX-2 expression detected by Western blotting with midbrain lysates showed minimal induction following MPTP administration in ASK1−/− mice compared to the robust induction one day after MPTP in wild-type animals (Fig. 5E). The latter finding suggests that ASK1 is a key player in MPTP-induced COX-2 expression and subsequent microglia activation.
(A, B) Immunohistochemistry with the microglial marker Iba1 (polyclonal, 1∶2,000) of nigral (SNc) and striatal (ST) sections. Scale bar = 100 µm. (C) Quantification of nigral Iba1 immunopositivity. * p<0.001. (D) Quantification of striatal Iba1 immunopositivity. * p<0.001. Quantifications were done using ImageJ. (E) MPTP-induced COX-2 expression is attenuated in ASK1−/− mice. Midbrains containing substantia nigra were homogenized and lysed for Western blotting for COX-2. Samples from two different mice per group are shown. * p<0.001. WT-Saline (n = 4), WT-MPTP-1 day (n = 4), WT-MPTP-3 day (n = 4); ASK1−/−-Saline (n = 3), ASK1−/−-MPTP-1 day (n = 4), ASK1−/−-MPTP-3 day (n = 3).
We also assessed activation of astroglial cells using immunohistochemistry for glial fibrillary acidic protein (GFAP) 1 day and 3 days after acute MPTP exposure. MPTP induced strong activation of GFAP positive cells in the nigra (Fig. 6A) and striatum (Fig. 6B) of wild-type mice particularly at 3 days, compared to a significantly blunted response in both these brain regions of ASK1−/− mice, suggesting that ASK1 is required for MPTP-induced astrocyte activation as well.
(A, B) Immunohistochemistry for GFAP in nigral (SNc) and striatal (ST) sections. Scale bar = 100 µm. (C) Quantification of nigral GFAP immunopositivity. * p<0.01; **<0.001. (D) Quantification of striatal GFAP immunopositivity. ** p<0.001. Quantifications were done using ImageJ. WT-Saline (n = 4), WT-MPTP-1 day (n = 4), WT-MPTP-3 day (n = 4); ASK1−/−-Saline (n = 3), ASK1−/−-MPTP-1 day (n = 4), ASK1−/−-MPTP-3 day (n = 3).
Discussion
In the present study, we have found that ASK1 deficiency partially protects the nigrostriatal dopaminergic system against MPTP-induced neurotoxicity and inhibits microglia and astrocyte activation. We also show that the behavioral benefits of ASK1 deletion correlate well with the observed cellular protection. These findings collectively suggest that ASK1 plays an important role in MPTP-induced toxicity in vivo.
Evidence is accumulating that chronic inflammation exacerbates the pathology in a number of neurodegenerative diseases including PD [28]. The innate immune cells of the brain, such as reactive astrocytes and microglia are abundant in the substantia nigra of PD [29], indicating a robust inflammatory state. Additionally, reactive microglial cells are seen in the basal ganglia in the 6-OHDA, MPTP and rotenone induced animal models of PD [30], [31], [32]. Further, α-synuclein, which aggregates in the characteristic inclusions in vulnerable neurons in PD patient brains, activates microglia and astrocytes in several PD models [33], [34], [35], [36]. However, it remains controversial whether activation of glial cells is favorable or detrimental to neurons. Our data suggest a detrimental role of activated glia in the neurodegenerative process, as the neuroprotection conferred by ASK1 deficiency correlates with a markedly attenuated glial response.
The mechanism by which MPTP leads to microglia activation remains obscure. Relevant to earlier reports that COX-2 mediates MPTP-induced microglia activation and subsequent dopamine neuron toxicity [26], [27], our results show that ASK1 is required for MPTP-induced COX-2 expression. This suggests that the role of ASK1 in regulating microglia activation is in part through regulating COX-2 expression [25]. Contrary to ASK1 deletion, JNK ablation reportedly does not interfere with microglia activation in the MPTP model, although targeted deletion of JNK protects dopaminergic neurons from MPTP toxicity [26]. Therefore, we speculate that the signal that leads to microglia activation is relayed from ASK1 to molecules other than JNK. In light of this notion, it is noteworthy that the phosphorylation of p38 MAP kinase, which is another kinase downstream of ASK1 [7], is observed within dopamine neurons in MPTP-lesioned mice, whereas JNK activation occurs primarily in microglia [37]. Further, the increased staining of phosphorylated p38 kinase in surviving nigral dopamine neurons in human brain sections from PD patients compared to age-matched controls provides further support for a role of p38 kinase in the degeneration of dopaminergic neurons [37]. A more direct relationship between ASK1 and p38 kinase has been shown in a study demonstrating that ASK1 is required for lipopolysaccharide (LPS)-induced activation of p38 but not of JNK in splenocytes and dendritic cells [38].
ASK1 is required for Toll-like receptor 4 (TLR4)-mediated mammalian innate immunity [38]. Splenocytes and dendritic cells isolated from ASK1−/− mice lose the ability to express proinflammatory cytokines such as TNF-α, IL-1 and IL-6 following LPS stimulation. In addition, ASK1 is required for chemokine production in astrocytes through several TLRs, and ASK1 deficiency attenuates neuroinflammation in the experimental autoimmune encephalomyelitis model in mice [39]. Collectively, these results indicate that ASK1 is expressed in these immune/glial cells and plays a role in their cell signaling. Therefore, we postulate that the attenuated glial activation upon MPTP exposure in ASK1−/− mice results from the effects of ASK1 deficiency in these cells. Based on Western blotting and RT-PCR with primary cell cultures, ASK1 is expressed in both microglia and astrocytes as well as in neurons including TH positive nigral dopaminergic neurons. We, therefore, hypothesize that ASK1 in dopamine neurons relays the signal(s) originated from MPP+ to produce the molecule(s) responsible for glial activation, although the nature of these molecules remains to be characterized. It is conceivable that α-synuclein released from dying dopamine neurons contributes to this event [33], [34]. In addition, ASK1 in glial cells may propagate the signal(s) conveyed from sick neurons finally resulting in glial activation and, in turn, further dopamine neuron injury.
In conclusion, our data provide evidence that ASK1 mediates microglia and astrocyte activation and MPTP-induced neurotoxicity, and that deletion of ASK1 prevents degeneration of DA neurons and glial activation. These findings suggest that ASK1 may serve as a potential target for the development of therapeutic interventions to slow or halt PD progression.
Materials and Methods
Cell and primary cultures
Human neuroblastoma SH-SY5Y cells (ATCC) were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) (Invitrogen) in a CO2 incubator at 37°C.
To prepare primary neuronal cultures, cortical tissue from E18 embryos of Sprague Dawley rats (Charles River) were recovered as described previously [40] under a protocol (# I08-034) approved by the Institutional Animal Care and Use Committee at the UMDNJ-Robert Wood Johnson Medical School. Tissues were minced and cells dissociated mechanically by gentle passaging through a flame-polished pasteur pipette in Neurobasal medium (Invitrogen). Cells were then passed through a strainer (45 µM pore size) and rinsed once in final culture medium (Neurobasal medium with B27 serum-free supplements, 0.5 mM L-glutamine, 0.1 IU/ml penicillin and 10 µg/ml streptomycin). Dissociated cells were plated at a density of 2×105 per cm2 in 100 µg/ml poly-D-lysine coated plates, and 1 µM cytosine arabinoside was added to the medium.
In vitro ASK1 Activity Assay
Cells were challenged with 5 mM MPP+ (Sigma) for the indicated times, and lysates were processed for immunoprecipitation with anti-ASK1 antibody (H-300, Santa Cruz Biotechnology). The immunoprecipitated complex was used for in vitro kinase assay in a reaction buffer consisting of 20 mM Tris-HCl (pH 7.5), 20 mM MgCl2, 5 µCi [γ-32P] ATP for 20 min at 30°C using myelin basic protein (MBP) (40 µg/ml) as substrate. Samples were resolved in SDS-PAGE and subjected to autoradiography.
Animals and MPTP Administration
ASK1 knockout mice were maintained on the C57BL/6J background as described previously [7]. All animals were handled in accordance with the NIH guidelines for the use of laboratory animals under a protocol (# I07-011-2) approved by the Institutional Animal Care and Use Committee at the UMDNJ-Robert Wood Johnson Medical School. Three-month-old wild-type and ASK1−/− male mice were challenged intraperitoneally with MPTP dissolved in sterile saline. Control animals received saline injections. Injection paradigms and doses are described in the Results section.
Western Blot
Cells and tissues were lysed with RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate) containing phosphatase inhibitor cocktail set II (Calbiochem, La Jolla, CA) and protease inhibitor cocktail set V (Calbiochem, La Jolla, CA). Lysates were separated in 4–12% gradient gel (Invitrogen). Primary antibodies used for Western blots and immunohistochemistry in these studies were as follows: anti-ASK1 (H-300) (Santa Cruz Biotechnology), anti-phospho-ASK1 (generated against the ASK1 epitope that contains p-Thr845) [41], anti-TH (Sigma), anti-GFAP (DAKO), anti-Iba1 (Wako), anti-COX-2 (BD Bioscience), and anti-β-actin (Sigma). Secondary antibodies (Sigma), anti-rabbit IgG-HRP or anti-mouse IgG-HRP were used with an enhanced chemiluminescence (ECL) kit (PerkinElmer LAS) for signal generation on X-ray film.
Immunohistochemistry and Stereology
Mice were perfused transcardially with PBS, and brains were removed and post-fixed in 4% paraformaldehyde at 4°C overnight. Free-floating, 40 µm thick coronal sections were incubated with the indicated primary antibodies overnight, followed by staining with the ABC kit (Vector Laboratories).
For counting nigral dopaminergic neurons, coronal 40-µm-thick sections were cut through the entire substantia nigra (SN). The SN pars compacta and medial ventral tegmental area regions were outlined for neuron counting according to previous anatomical demarcations of the midbrain dopaminergic neurons in the mouse [42]. Every fourth section through the rostral–caudal extent of the SN was stained with an antibody against tyrosine hydroxylase (TH, 1∶4000; Sigma) and processed with the ABC method. Tissue sections were counterstained with cresyl violet, a Nissl stain, and cover-slipped. StereoInvestigator software (version 8.0. MicroBrightfield Inc., Williston, VT) was used to count TH-immunoreactive (TH-IR) cells and Nissl-stained cells. Cells were counted with a 100× oil immersion objective (1.3 NA) using a Leica DMRE microscope. The cell counting frame was 50×50×5 µm with a 1 µm upper and lower guard zone. A cell was defined as a TH-IR soma with a clearly visible unstained nucleus. For Nissl-stained cells, a cell was defined as a non-TH-containing soma in focus within the counting frame. The TH cell counts were taken from 6 sections, spaced 4 apart (120 µm) and 200–250 cells were counted in the SN on one side of the brain. For Nissl cell counting, the same sections were examined. TH-containing cells represent dopaminergic neurons, and cresyl-violet stained neurons represent all other nondopaminergic neurons.
Measurement of Striatal Dopamine, MPP+ and TH
Mice were killed after MPTP or saline injections at time points specified in the Results section, and their striata were quickly dissected. Striatal dopamine and its metabolites were measured by HPLC-electrochemical detection as described previously [43]. Striatal levels of MPP+ were measured by HPLC using UV detection. Striatal tyrosine hydroxylase content was measured by an enzyme-linked immunosorbent assay method [44].
Behavior Assessments
Motor coordination and motor learning were measured by the rotarod test. Mice were placed on a rotating cylinder (diameter = 4.5 cm) with a coarse surface for a firm grip and tested for three trials with an accelerating speed of 0.2 rpm/second, increasing from 4 to 40 rpm. A cut-off time of 3 min and an inter-trial interval of 60 min were used. The latency of time spent on the rod before falling was measured.
To assess nest-building performance, each mouse was housed in a cage containing a single block of nesting material (NestletsTM, Ancare Corp) for 18 h. Each cage was then scored blindly depending on the condition of nesting material on a scale ranging from 0 = non shredded to 5 = maximally shredded [45].
Author Contributions
Conceived and designed the experiments: EJ MMM. Performed the experiments: K-WL XZ J-YI HG WHJ TWC PKS DCG. Analyzed the data: K-WL WHJ PKS DCG EJ MMM. Contributed reagents/materials/analysis tools: HI. Wrote the paper: K-WL DCG EJ MMM.
References
- 1. Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53: Suppl 3S26–36; discussion S36–28.
- 2. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, et al. (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46: 598–605.
- 3. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, et al. (2000) MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30: 171–182.
- 4. Cookson MR (2005) The biochemistry of Parkinson's disease. Annu Rev Biochem 74: 29–52.
- 5. Junn E, Taniguchi H, Jeong BS, Zhao X, Ichijo H, et al. (2005) Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc Natl Acad Sci U S A 102: 9691–9696.
- 6. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, et al. (1997) Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275: 90–94.
- 7. Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, et al. (2001) ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2: 222–228.
- 8. Chang HY, Nishitoh H, Yang X, Ichijo H, Baltimore D (1998) Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. Science 281: 1860–1863.
- 9. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, et al. (1998) Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596–2606.
- 10. Song JJ, Rhee JG, Suntharalingam M, Walsh SA, Spitz DR, et al. (2002) Role of glutaredoxin in metabolic oxidative stress. Glutaredoxin as a sensor of oxidative stress mediated by H2O2. J Biol Chem 277: 46566–46575.
- 11. Nishitoh H, Matsuzawa A, Tobiume K, Saegusa K, Takeda K, et al. (2002) ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev 16: 1345–1355.
- 12. Liu H, Nishitoh H, Ichijo H, Kyriakis JM (2000) Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin. Mol Cell Biol 20: 2198–2208.
- 13. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, et al. (2007) Genome-wide atlas of gene expression in the adult mouse brain. Nature 445: 168–176.
- 14. Takeda K, Hatai T, Hamazaki TS, Nishitoh H, Saitoh M, et al. (2000) Apoptosis signal-regulating kinase 1 (ASK1) induces neuronal differentiation and survival of PC12 cells. J Biol Chem 275: 9805–9813.
- 15. Nishitoh H, Kadowaki H, Nagai A, Maruyama T, Yokota T, et al. (2008) ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev 22: 1451–1464.
- 16. Hu X, Weng Z, Chu CT, Zhang L, Cao G, et al. (2011) Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade. J Neurosci 31: 247–261.
- 17. Noguchi T, Takeda K, Matsuzawa A, Saegusa K, Nakano H, et al. (2005) Recruitment of tumor necrosis factor receptor-associated factor family proteins to apoptosis signal-regulating kinase 1 signalosome is essential for oxidative stress-induced cell death. J Biol Chem 280: 37033–37040.
- 18. Karunakaran S, Diwakar L, Saeed U, Agarwal V, Ramakrishnan S, et al. (2007) Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid. FASEB J 21: 2226–2236.
- 19. Saeed U, Karunakaran S, Meka DP, Koumar RC, Ramakrishnan S, et al. (2009) Redox activated MAP kinase death signaling cascade initiated by ASK1 is not activated in female mice following MPTP: novel mechanism of neuroprotection. Neurotox Res 16: 116–126.
- 20. Sager TN, Kirchhoff J, Mork A, Van Beek J, Thirstrup K, et al. (2010) Nest building performance following MPTP toxicity in mice. Behav Brain Res 208: 444–449.
- 21. Upchurch M, Schallert T (1983) A behavior analysis of the offspring of “haloperidol-sensitive” and “haloperidol-resistant” gerbils. Behav Neural Biol 39: 221–228.
- 22. Kumakura K, Nomura H, Toyoda T, Hashikawa K, Noguchi T, et al. (2010) Hyperactivity in novel environment with increased dopamine and impaired novelty preference in apoptosis signal-regulating kinase 1 (ASK1)-deficient mice. Neurosci Res 66: 313–320.
- 23. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, et al. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22: 1763–1771.
- 24. Kim YS, Choi DH, Block ML, Lorenzl S, Yang L, et al. (2007) A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J 21: 179–187.
- 25. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, et al. (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A 100: 5473–5478.
- 26. Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, et al. (2004) JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 101: 665–670.
- 27. Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL, et al. (2006) Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflammation 3: 6.
- 28. Hunot S, Hirsch EC (2003) Neuroinflammatory processes in Parkinson's disease. Ann Neurol 53: Suppl 3S49–58; discussion S58–60.
- 29. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson's disease. Mov Disord 23: 474–483.
- 30. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, et al. (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15: 991–998.
- 31. Sugama S, Yang L, Cho BP, DeGiorgio LA, Lorenzl S, et al. (2003) Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 964: 288–294.
- 32. Gao HM, Liu B, Hong JS (2003) Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 23: 6181–6187.
- 33. Zhang W, Wang T, Pei Z, Miller DS, Wu X, et al. (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. Faseb J 19: 533–542.
- 34. Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, et al. (2008) Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging 29: 1690–1701.
- 35. Lee EJ, Woo MS, Moon PG, Baek MC, Choi IY, et al. (2010) Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol 185: 615–623.
- 36. Lee KW, Chen W, Junn E, Im JY, Grosso H, et al. (2011) Enhanced phosphatase activity attenuates alpha-Synucleinopathy in a mouse model. J Neurosci 31: 6963–6971.
- 37. Karunakaran S, Saeed U, Mishra M, Valli RK, Joshi SD, et al. (2008) Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. J Neurosci 28: 12500–12509.
- 38. Matsuzawa A, Saegusa K, Noguchi T, Sadamitsu C, Nishitoh H, et al. (2005) ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol 6: 587–592.
- 39. Guo X, Harada C, Namekata K, Matsuzawa A, Camps M, et al. (2010) Regulation of the severity of neuroinflammation and demyelination by TLR-ASK1-p38 pathway. EMBO Mol Med 2: 504–515.
- 40. Zeevalk GD, Manzino L, Sonsalla PK, Bernard LP (2007) Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp Neurol 203: 512–520.
- 41. Tobiume K, Saitoh M, Ichijo H (2002) Activation of apoptosis signal-regulating kinase 1 by the stress-induced activating phosphorylation of pre-formed oligomer. J Cell Physiol 191: 95–104.
- 42. Nelson EL, Liang CL, Sinton CM, German DC (1996) Midbrain dopaminergic neurons in the mouse: computer-assisted mapping. J Comp Neurol 369: 361–371.
- 43. Sonsalla PK, Riordan DE, Heikkila RE (1991) Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J Pharmacol Exp Ther 256: 506–512.
- 44. Alfinito PD, Wang SP, Manzino L, Rijhsinghani S, Zeevalk GD, et al. (2003) Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J Neurosci 23: 10982–10987.
- 45. Deacon RM (2006) Assessing nest building in mice. Nat Protoc 1: 1117–1119.